Karyopharm Q2 Revenue Dips, Net Loss Narrows Amid Cost Cuts

TL;DR

**KPTI's cost-cutting is masking weak XPOVIO sales; watch for sustained revenue growth or prepare for further dilution.**

AI Summary

Karyopharm Therapeutics Inc. reported total revenue of $34.7 million for the three months ended June 30, 2025, a decrease from $38.9 million in the prior-year period. Product revenue for the quarter was $29.8 million, down from $33.6 million year-over-year. The company's net loss for the three months ended June 30, 2025, was $45.2 million, an improvement from a net loss of $55.1 million in the same period of 2024. Research and development expenses decreased to $30.1 million from $38.5 million, while selling, general, and administrative expenses also saw a reduction to $35.8 million from $40.2 million. Karyopharm entered into an Open Market Sale Agreement with Jefferies LLC in Q1 2025, selling 1,300,000 shares of common stock for net proceeds of $4.0 million. The company also issued 3.00% Convertible Senior Notes due 2025, with a principal amount of $150.0 million outstanding as of June 30, 2025. A significant risk highlighted is the dependence on XPOVIO sales and the potential for increased competition.

Why It Matters

Karyopharm's mixed Q2 results, with declining revenue but improved net loss due to cost controls, signal a challenging but potentially stabilizing period for investors. The decrease in XPOVIO sales, a key product, raises concerns about market penetration and competitive pressures from other oncology treatments. For employees, continued cost-cutting measures could imply workforce adjustments, while customers might see shifts in product focus or support. The broader market will watch Karyopharm's ability to grow its core product in a highly competitive pharmaceutical landscape, especially with the 3.00% Convertible Senior Notes due 2025 posing a near-term financial consideration.

Risk Assessment

Risk Level: medium — The risk level is medium due to declining product revenue from XPOVIO, which fell from $33.6 million in Q2 2024 to $29.8 million in Q2 2025. This is partially offset by a reduction in net loss from $55.1 million to $45.2 million, driven by lower R&D and SG&A expenses, indicating operational improvements but also potential challenges in top-line growth.

Analyst Insight

Investors should monitor Karyopharm's upcoming quarters for signs of XPOVIO revenue stabilization or growth, as current cost reductions may not be sustainable without top-line improvement. Evaluate the company's strategy for the 3.00% Convertible Senior Notes due 2025, as their maturity could impact liquidity and future financing needs.

Financial Highlights

debt To Equity

N/A

revenue

$34.7M

operating Margin

N/A

total Assets

N/A

total Debt

$150.0M

net Income

-$45.2M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

-11.3%

Revenue Breakdown

Key Numbers

• $34.7M — Total Revenue (Decreased from $38.9M in Q2 2024, indicating top-line pressure.)
• $29.8M — Product Revenue (Down from $33.6M in Q2 2024, highlighting challenges for XPOVIO.)
• $45.2M — Net Loss (Improved from $55.1M in Q2 2024, driven by cost reductions.)
• $30.1M — R&D Expenses (Decreased from $38.5M in Q2 2024, reflecting cost control efforts.)
• $35.8M — SG&A Expenses (Reduced from $40.2M in Q2 2024, contributing to a narrower net loss.)
• $150.0M — Convertible Senior Notes (Principal amount due 2025, a significant near-term financial obligation.)
• 1,300,000 — Shares Sold (Through ATM offering, generating $4.0M in net proceeds.)

Key Players & Entities

• Karyopharm Therapeutics Inc. (company) — filer of the 10-Q
• Jefferies LLC (company) — underwriter for Open Market Sale Agreement
• Antengene Therapeutics Limited (company) — licensee for royalty revenue
• Menarini (company) — licensee for royalty revenue
• Healthcare Royalty Partners IV, L.P. (company) — partner in revenue interest financing agreement
• XPOVIO (product) — Karyopharm's primary oncology drug
• $34.7 million (dollar_amount) — total revenue for Q2 2025
• $29.8 million (dollar_amount) — product revenue for Q2 2025
• $45.2 million (dollar_amount) — net loss for Q2 2025
• $150.0 million (dollar_amount) — principal amount of 3.00% Convertible Senior Notes due 2025

FAQ

Risk Factors

• Dependence on XPOVIO [high — market]: The company's financial performance is heavily reliant on the sales of its primary product, XPOVIO. Any decline in demand or increased competition could significantly impact revenue and profitability.
• Convertible Senior Notes Maturity [high — financial]: Karyopharm has $150.0 million in 3.00% Convertible Senior Notes due in 2025. The repayment or refinancing of this debt represents a significant near-term financial obligation.
• Competitive Landscape [medium — market]: The pharmaceutical market is highly competitive. Increased competition for XPOVIO or the emergence of superior therapies could erode market share and pricing power.
• R&D and SG&A Cost Management [medium — operational]: While R&D expenses decreased to $30.1M (from $38.5M) and SG&A to $35.8M (from $40.2M), continued effective cost management is crucial to achieve profitability given the current revenue levels.

Industry Context

The oncology pharmaceutical market is characterized by high R&D costs, long development cycles, and intense competition. Companies like Karyopharm focus on developing novel therapies for unmet medical needs, often relying on a few key products for revenue. Regulatory approvals and market access are critical success factors.

Regulatory Implications

Karyopharm operates under strict FDA regulations for drug approval and marketing. Any changes in regulatory requirements or adverse findings could impact XPOVIO's market status and future product development. Compliance with post-market surveillance is also essential.

What Investors Should Do

1. Monitor XPOVIO sales trends closely.
2. Assess the company's plan for the 2025 convertible note maturity.
3. Evaluate the effectiveness of cost reduction measures.

Key Dates

• 2025-06-30: Quarter End Date — Reporting period for the 10-Q filing, showing financial performance for Q2 2025.
• 2025-08-11: Filing Date — Date the 10-Q was filed with the SEC.
• 2025: Convertible Senior Notes Due — Maturity date for the $150.0 million in convertible notes, requiring repayment or refinancing.

Glossary

XPOVIO

Karyopharm's primary drug product, used for treating certain types of cancer. (The main driver of the company's product revenue, making its sales performance critical.)

Open Market Sale Agreement

An agreement allowing a company to sell its shares of common stock over time through a broker at prevailing market prices. (Used by Karyopharm to raise $4.0 million in net proceeds in Q1 2025, impacting share count and cash position.)

Convertible Senior Notes

Debt securities that can be converted into a predetermined amount of the issuer's equity (common stock). (Represents a significant debt obligation of $150.0 million due in 2025, with implications for future dilution and cash flow.)

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial and operational information for Karyopharm's second quarter of 2025.)

Year-Over-Year Comparison

Total revenue for Q2 2025 was $34.7 million, a decrease from $38.9 million in Q2 2024, indicating top-line pressure. Product revenue also declined to $29.8 million from $33.6 million year-over-year. However, the net loss improved to $45.2 million from $55.1 million, driven by significant reductions in both R&D expenses (down from $38.5M) and SG&A expenses (down from $40.2M).

Key Financial Figures

• $0.0001 — on which registered Common Stock , $0.0001 par value KPTI Nasdaq Global Select

Filing Documents

• kpti-20250630.htm (10-Q) — 3300KB
• kpti-ex10_1.htm (EX-10.1) — 33KB
• kpti-ex31_1.htm (EX-31.1) — 12KB
• kpti-ex31_2.htm (EX-31.2) — 12KB
• kpti-ex32_1.htm (EX-32.1) — 8KB
• kpti-ex32_2.htm (EX-32.2) — 8KB
• 0000950170-25-106238.txt ( ) — 10994KB
• kpti-20250630.xsd (EX-101.SCH) — 1241KB
• kpti-20250630_htm.xml (XML) — 1904KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 2 Item 1. Condensed Consolidated Financial Statements (Unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations 3 Condensed Consolidated Statements of Comprehensive Income (Loss) 4 Condensed Consolidated Statements of Cash Flows 5 Condensed Consolidated Statements of Stockholders' Deficit 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

- OTHER INFORMATION

PART II - OTHER INFORMATION 30 Item 1A.

Risk Factors

Risk Factors 30 Item 5. Other Information 82 Item 6. Exhibits 83

Signatures

Signatures 84 1 Table of Contents

- FINANCI AL INFORMATION

PART I - FINANCI AL INFORMATION

Condensed Consolid ated Financial Statements (Unaudited)

Item 1. Condensed Consolid ated Financial Statements (Unaudited). KARYOPHARM THERAPEUTICS INC. CONDENSED CONSOLIDAT ED BALANCE SHEETS (unaudited) (in thousands, except per share amounts) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 38,725 $ 62,476 Investments 12,972 46,236 Accounts receivable, net 32,932 30,766 Inventory 4,992 4,739 Prepaid expenses and other current assets 8,249 12,245 Total current assets 97,870 156,462 Property and equipment, net 244 400 Operating lease right-of-use assets 5,081 5,884 Restricted cash 350 338 Other assets 1,334 1,334 Total assets $ 104,879 $ 164,418 Liabilities and stockholders' deficit Current liabilities: Accounts payable $ 2,597 $ 5,107 Accrued expenses 62,929 60,652 Convertible senior notes due 2025 24,484 24,426 Senior secured term loan 6,250 — Operating lease liabilities 1,383 438 Other current liabilities 1,573 1,641 Total current liabilities 99,216 92,264 Convertible senior notes due 2029 62,684 68,345 Senior secured term loan, net of current portion 89,566 94,603 Deferred royalty obligation 73,499 73,499 Common stock warrants 4,333 12,582 Operating lease liabilities, net of current portion 6,251 6,712 Other liabilities 8,256 2,430 Total liabilities 343,805 350,435 Stockholders' deficit: Preferred stock, $ 0.0001 par value; 5,000 shares authorized; none issued and outstanding — — Common stock, $ 0.0001 par value; 53,333 shares authorized; 8,647 and 8,413 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 13 13 Additional paid-in capital 1,385,486 1,377,786 Accumulated other comprehensive loss ( 251 ) ( 356 ) Accumulated deficit ( 1,624,174 ) ( 1,563,460 ) Total stockholders' deficit ( 238,926 ) ( 186,017 ) Total liabiliti

View Full Filing

View this 10-Q filing on SEC EDGAR